UY39006A - Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting - Google Patents
Compuestos y composiciones para tratar afecciones asociadas con la actividad de stingInfo
- Publication number
- UY39006A UY39006A UY0001039006A UY39006A UY39006A UY 39006 A UY39006 A UY 39006A UY 0001039006 A UY0001039006 A UY 0001039006A UY 39006 A UY39006 A UY 39006A UY 39006 A UY39006 A UY 39006A
- Authority
- UY
- Uruguay
- Prior art keywords
- sting
- compositions
- compounds
- conditions associated
- treat conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955839P | 2019-12-31 | 2019-12-31 | |
| US202063090538P | 2020-10-12 | 2020-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39006A true UY39006A (es) | 2021-07-30 |
Family
ID=74206237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039006A UY39006A (es) | 2019-12-31 | 2020-12-30 | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230127839A1 (https=) |
| EP (1) | EP4085051A1 (https=) |
| JP (1) | JP7756643B2 (https=) |
| CN (2) | CN120965654A (https=) |
| PY (1) | PY2089159A (https=) |
| TW (1) | TW202136239A (https=) |
| UY (1) | UY39006A (https=) |
| WO (1) | WO2021138434A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112823036B (zh) | 2018-07-03 | 2024-11-08 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| EP4267129A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| WO2022140397A1 (en) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Methods of treating cancer |
| US20240060982A1 (en) | 2020-12-22 | 2024-02-22 | Ifm Due, Inc. | Methods of treating cancer |
| EP4267128A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| TW202235073A (zh) | 2021-01-08 | 2022-09-16 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關的病狀之化合物及組合物 |
| JP2024502470A (ja) * | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| CN116981668A (zh) * | 2021-04-09 | 2023-10-31 | 百济神州(北京)生物科技有限公司 | 制备bcl-2抑制剂的中间体的方法 |
| UY39892A (es) | 2021-08-10 | 2023-03-31 | Novartis Pharma Ag | Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN117756698A (zh) * | 2022-12-16 | 2024-03-26 | 中国药科大学 | 脲类化合物及其作为sting抑制剂的医药用途 |
| CN116023321B (zh) * | 2022-12-30 | 2024-11-29 | 中国药科大学 | Sting抑制剂前药及其医药用途 |
| CN120794982A (zh) * | 2024-05-14 | 2025-10-17 | 中国药科大学 | 吡唑类sting抑制剂及其医药用途 |
| CN120794957A (zh) * | 2024-05-14 | 2025-10-17 | 中国药科大学 | 苯并含氮杂环类sting抑制剂及其医药用途 |
| WO2026023667A1 (ja) * | 2024-07-25 | 2026-01-29 | カルナバイオサイエンス株式会社 | フェニルピペラジン誘導体 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5783558A (en) * | 1980-11-13 | 1982-05-25 | Asahi Chem Ind Co Ltd | Novel organic compound and its preparation |
| JPS5783557A (en) * | 1980-11-14 | 1982-05-25 | Asahi Chem Ind Co Ltd | Novel azomethine compound and its preparation |
| US20120046290A1 (en) * | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
| WO2003028720A1 (en) * | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| DE102005038947A1 (de) * | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| WO2012062462A1 (en) * | 2010-11-10 | 2012-05-18 | Grünenthal GmbH | Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands |
| WO2012075380A1 (en) | 2010-12-03 | 2012-06-07 | The Trustees Of The University Of Pennsylvania | Tip60 inhibitors |
| CN102516153B (zh) * | 2011-12-14 | 2014-03-12 | 南京工业大学 | 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用 |
| CA2914815A1 (en) * | 2013-06-11 | 2014-12-18 | Kala Pharmaceuticals, Inc. | Urea derivatives and uses thereof |
| CN109394752A (zh) | 2013-10-21 | 2019-03-01 | 德雷克塞尔大学 | 治疗慢性乙型肝炎病毒感染的sting激动剂的用途 |
| CN107417478B (zh) * | 2017-06-05 | 2020-05-05 | 南京师范大学 | 一种催化氧化羰基化合成不对称二取代脲的方法 |
| EP3556362A1 (en) * | 2018-04-16 | 2019-10-23 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| WO2020191227A1 (en) * | 2019-03-20 | 2020-09-24 | Cornell University | Methods for controlling prostaglandin-mediated biological processes |
| EP4267128A1 (en) * | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| EP4267129A1 (en) * | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| WO2022140397A1 (en) * | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Methods of treating cancer |
| US20240060982A1 (en) * | 2020-12-22 | 2024-02-22 | Ifm Due, Inc. | Methods of treating cancer |
-
2020
- 2020-12-30 JP JP2022540328A patent/JP7756643B2/ja active Active
- 2020-12-30 CN CN202511145327.2A patent/CN120965654A/zh active Pending
- 2020-12-30 PY PY202002089159A patent/PY2089159A/es unknown
- 2020-12-30 UY UY0001039006A patent/UY39006A/es unknown
- 2020-12-30 US US17/789,694 patent/US20230127839A1/en active Pending
- 2020-12-30 TW TW109146905A patent/TW202136239A/zh unknown
- 2020-12-30 CN CN202080097901.0A patent/CN115348957B/zh active Active
- 2020-12-30 WO PCT/US2020/067483 patent/WO2021138434A1/en not_active Ceased
- 2020-12-30 EP EP20845545.1A patent/EP4085051A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202136239A (zh) | 2021-10-01 |
| PY2089159A (es) | 2022-05-11 |
| EP4085051A1 (en) | 2022-11-09 |
| CN115348957A (zh) | 2022-11-15 |
| CN115348957B (zh) | 2025-11-25 |
| JP2023509422A (ja) | 2023-03-08 |
| US20230127839A1 (en) | 2023-04-27 |
| CN120965654A (zh) | 2025-11-18 |
| WO2021138434A1 (en) | 2021-07-08 |
| JP7756643B2 (ja) | 2025-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39006A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY38751A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY38905A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY39005A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY39608A (es) | Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting | |
| PY2157405A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting | |
| CO2019008932A2 (es) | Imidazo-quinolinas sustituidas como moduladores de nlrp3 | |
| MX2018012249A (es) | Moduladores de nlpr3. | |
| EA201891565A1 (ru) | Соединения и композиции для лечения состояний, ассоциированных с активностью sting | |
| MX2020003868A (es) | Compuesto heterociclico como inhibidor de proteina quinasa. | |
| ECSP24044340A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| WO2022133046A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| MX2022000271A (es) | Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos. | |
| ECSP24015990A (es) | Compuestos y composiciones para tratar condiciones asociadas con actividad de sting | |
| UY40106A (es) | Compuestos y composiciones para tratar afecciones relacionadas con la actividad de STING | |
| AR111693A1 (es) | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga | |
| MX2021005561A (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco. | |
| MX2017009449A (es) | Inhibidor jak. | |
| MX2025012450A (es) | Inhibidores de prmt5 y usos de estos | |
| MX2020003593A (es) | Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos. | |
| MX382757B (es) | Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| AR099068A1 (es) | Anticuerpo anti-netrina-1 | |
| MX394782B (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfunción mitocondrial. | |
| MX2021003904A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. |